![]() |
|
|
Vol. 53, Issue 3, 467-474, March 1998
Pharmacological Institutes and Drug Research and Development Group,
| |
Summary |
|---|
|
|
|---|
We obtained a primary culture of prostatic cells through explantation from patients with benign prostatic hyperplasia. Structural morphology, immunohistochemical staining, and growth characteristics of these cells demonstrate that they are consistent with the population of smooth muscle cells (SMCs). We examined the influence of a nitric oxide donor, sodium nitroprusside (SNP), on the regulation of human prostatic SMC proliferation. SNP exhibited a concentration-dependent (0.1-10 µM) inhibition of fetal calf serum-induced proliferation in human prostatic SMCs. In addition, growth-inhibitory responses to 8-bromo-cGMP (1-30 µM) were observed. However, the responses to SNP were significantly diminished by the presence of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (3 µM; a selective guanylate cyclase inhibitor). Furthermore, SNP induced an increased concentration-dependent accumulation of intracellular cGMP in human prostatic SMCs. After 48-hr period of deprivation of serum, cells were restimulated with serum to permit cell cycle progression. The addition of SNP (10 µM) at various times after the addition of serum to serum-deprived cells showed maximal inhibition of cell proliferation even when added 6 hr after the serum. This blocking effect of cell cycle progression was lost gradually as the delay from serum to SNP application increased from 6 to 18 hr. The membrane-associated protein kinase C (PKC) activity was studied in human prostatic SMCs; results showed that fetal calf serum (10%, v/v) significantly increased membrane-associated PKC activity. SNP (10 µM), which had little effect on basal kinase activity, completely abolished serum-induced augmentation of PKC activity. Therefore, we suggest that SNP mediates its antiproliferative effect by the inhibition of PKC activity on human prostatic SMCs; furthermore, its antiproliferative effect occurs at the early G1 phase of the cell cycle.
| |
Introduction |
|---|
|
|
|---|
BPH
is one of the most common diseases in elderly men and is characterized
by abnormal proliferation of the stromal and epithelial cells of the
prostate. Despite the high frequency of its occurrence, we still have
little insight into the fundamental causes of BPH at the cellular
level. SMCs constitute a major cellular component of prostatic stroma
(Shapiro et al., 1992
). In addition, SMC proliferation and
tension play important roles in bladder outflow obstruction secondary
to BPH (Tenniswood et al., 1992
; Moriyama et al.,
1994
; Guh et al., 1995
). Therefore, it is important to know
the physiological and pathological effects and their mechanisms of
action in prostatic SMCs.
Recently, Burnett et al. (1995)
used biochemical and
immunohistochemical analyses to characterize the localization of NOS in
the human prostate. Their results revealed NOS activity in this tissue,
and it is proposed that NO may modulate smooth muscle tone in the human
prostate. In addition, Takeda et al. (1995)
conducted
functional pharmacological experiments and used electrical field
stimulation to investigate the effects of NO on human prostates. They
provided evidence that NO plays a role in mediation of the contractile
function of human prostate. In addition to the roles on contractile
activity, NO and NO donor have roles in growth regulation of several
types of cells. They exhibit antiproliferative effects on rat vascular
SMCs (Nakaki et al., 1990
; Shimizu et al., 1991
;
Etienne et al., 1996
), bovine pulmonary arterial SMCs (Lee
et al., 1996
), and rabbit aortic SMCs (Kariya et
al., 1989
). Nevertheless, there has been no study to investigate
whether NO, endogenously synthesized in human prostate, plays a role in
the regulation of human prostatic SMC proliferation.
Recently, we successfully used the explant culture method for the selective cultivation of human prostatic SMCs. These cultures are used to provide a useful model with which to investigate their roles in the development of BPH. The purpose of the current study was to investigate the effect of SNP, a NO donor, on the growth regulation of human prostatic SMCs. The mechanism of action and signal transduction occurring after the challenge to SNP also were examined.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
RPMI-1640 medium and all other tissue culture
reagents were obtained from GIBCO (Grand Island, NY). Testosterone;
mouse anti-vimentin, anti-cytokeratin, anti-smooth muscle
-actin,
anti-desmin, and fluorescein-conjugated goat anti-mouse IgG; MTT;
-isopropanol; 8-bromo-cGMP; ODQ; EDTA (disodium salt); EGTA; and SNP
were purchased from Sigma Chemical (St. Louis, MO). cGMP enzyme
immunoassay kits were obtained from Cayman Chemical (Ann Arbor, MI).
[
-32P]ATP (3000 Ci/mmol) and PKC enzyme
assay kits were purchased from Amersham International (Buckinghamshire,
UK). Apoptosis detection kits were from Upstate Biotechnology (Lake
Placid, NY).
Human prostate tissues. Human hyperplastic prostates were obtained during surgery from four men through transurethral resection of the prostate. All these patients had histories of prostatism and were diagnosed as having BPH on the basis of the combination of rectal digital examinations, transrectal sonography of the prostate, and urodynamic studies (including uroflowmetry, urethral pressure profile, and cystometry).
Tissue explants and subcultures. Tissue specimens were immediately placed into a sterile Petri dish and minced into small pieces of ~2 × 2 × 2 mm under a laminar flow hood. The minced tissue pieces then were transferred into a 15-ml polypropylene centrifuge tube containing 3 ml of 0.1% collagenase type 1 in HBSS, pH 7.4, and bubbled with a mixture of 5% CO2/95% O2 at 37° for 40 min. The tube was subjected to a rotator at a speed of 300 rpm for 3 min. After a brief settlement, the supernatant fraction was discarded, and the tube was filled with 3 ml of 0.1% trypsin in PBS in the above condition for 10 min. The tissue pieces were centrifuged at a speed of 1000 rpm for 3 min, and then the pieces were washed twice with HBSS and transferred to sterile flasks, which were precoated with 10 µg/ml collagen type 1, containing RPMI-1640 medium supplemented with 10% FCS (v/v), penicillin (100 units/ml)/streptomycin (100 µg/ml), amphotericin B (2.5 mg/ml), and testosterone (10 nM). Cultures were maintained in a humidified incubator at 37° in 5% CO2/air. Usually with 5-7 days, successfully attached explants would have cells emanating around the tissue. After 1 week, the medium was changed and thereafter changed every 3 days. Once the cells in the flask reached confluence (~2-3 weeks), the explant was transferred to another flask and cultured to reach confluence. After this cultivation procedure was followed for five times, the cells that grew out of the explant were trypsinized from the fifth culture flask for subculture and split into a 1:3 ratio as soon as monolayers became confluent.
Immunofluorescence.
Isolated human prostatic cells were
plated onto a chamber slide (Falcon, Cowley, UK), cultured for 48 hr,
and fixed with 100% methanol for 5 min. After washing (three times)
with PBS, fixed cells were incubated (37°) with anti-vimentin,
anti-cytokeratin, anti-smooth muscle
-actin, or anti-desmin IgG
(dilution, 1:50-100) for 40 min. Cells were again washed (three times)
with PBS and incubated with fluorescein-conjugated goat anti-mouse IgG
(dilution, 1:100) for 40 min. Green fluorescence was evaluated using a
fluorescence microscope (Nikon).
Cell proliferation assay.
The cell proliferation assay was
carried out using the MTT assay described by Mosmann (1983)
. MTT was
dissolved in PBS at a concentration of 5 mg/ml and filtered (Millipore,
Bedford, MA). From this stock solution, 10 µl/100 µl of medium was
added to each well, and plates was gently shaken and incubated at 37°
for 4 hr. The treatment of living cells with MTT produces a dark-blue formazan product, whereas no staining is observed in dead cells. After
the loading of MTT, the medium was replaced with 100 µl of acidified
(0.04 M KCl)
-isopropanol and maintained for 20-30 min
at room temperature for color development; then, the 96-well plate was
read with an enzyme-linked immunosorbent assay reader (570 nm) to
obtain the absorbance values.
Assay of cGMP contents. Confluent and quiescent cultures were washed three times with PBS (37°) and then incubated in 1 ml of RPMI-1640 medium in the absence or presence of the indicated agents for 5 min. At the end of the specified incubation period, the medium was removed rapidly, and 0.5 ml of ice-cold trichloroacetic acid [10% (w/v)]/4 mM EDTA was added to the wells. After incubation for 30 min at 4°, cells were scraped, and the resulting suspensions were centrifuged at 10,000 × g for 5 min. The supernatants were removed and extracted four times with 3 volumes of ether. Next, the cGMP contents were assayed using enzyme immunoassay kits. Results are expressed as fmol/5 × 104 cells.
Assay of PKC activity.
Human prostatic SMCs were incubated
in RPMI-1640 medium in the absence or presence of SNP (10 µM) for 15 min at 37°. FCS [10% (v/v)] was added,
and the cells were incubated for an additional 10 min. The cells were
washed twice with ice-cold PBS, scraped into 0.5 ml of buffer A (0.25 M sucrose, 20 mM HEPES, 2 mM EDTA, 5 mM EGTA, 10 mM 2-mercaptoethanol, 0.21 mM leupetin, and 2 mM phenylmethylsulfonyl
fluoride, pH 7.5), and ultrasonically disrupted (20 sec at setting 5;
Vibra Cell, Sonics and Materials, Danbury, CT) at 4°. The homogenate
was centrifuged at 100,000 × g for 20 min at 4°. The
pellet (particulate fraction) was resuspended in 0.5 ml of buffer A
containing 0.2% Triton X-100, incubated at 4° for 60 min, and
centrifuged for 30 min at 50,000 × g at 4°. The
supernatant was used as a crude membrane extract. The crude extract was
loaded onto a DEAE-cellulose DE-52 column (Whatman, Maidstone, UK) in a
volume of ~0.5 ml. The column was washed with 1.5 ml of equilibration
buffer (20 mM Tris·HCl, 0.5 mM EGTA, 0.5 mM EDTA, 10 mM 2-mercaptoethanol, pH 7.5) and
12.5 ml of equilibration buffer containing 20 mM NaCl. PKC
was eluted with 1.5 ml of equilibration buffer containing 120 mM NaCl, and PKC activity was measured using a commercially
available kit (Amersham). Protein kinase assay mixture contained the
enzyme preparation (25 µl), reaction mixture (25 µl of 3 mM calcium acetate, 75 µg/ml phosphatidylserine, 6 µg/ml phorbol-12-myristate-13-acetate, 225 µM peptide,
7.5 mM dithiothreitol, 50 mM Tris·HCl), and
25 µl of [
-32P]ATP (10 µCi/ml) in a
final volume of 75 µl. After a 15-min incubation at 37°, reactions
were terminated by the addition of 10 ml of 300 mM
orthophosphoric acid. Terminated reaction mixture (35 µl) was
transferred onto the paper disc and dried for 5 min. The paper disc was
washed twice with 10 ml of orthophosphoric acid (75 mM). The PKC activity is calculated as P = T × 1000/IR pmol/min,
where T is total phosphate transferring to peptide, I is the incubation time (min), and R is the specific radioactivity/nmol of ATP. PKC activity was expressed as pmol of 32P
incorporated into peptide/min/106 cells.
In situ labeling of apoptotic cells.
A
commercial kit for detection of apoptotic cells was used in this study.
Cells were cultured on a chamber slide for 24 hr and then made
quiescent by serum deprivation for 48 hr. The cells were switched to
FCS-containing medium, with or without SNP (10 µM) for 48 hr. After removal of the medium, the cells were washed twice with PBS,
fixed for 1 min with ice-cold ethanol/acetic acid (1:1) solution, and
then washed three times with PBS. The fixed cells were permeabilized in
ice-cold 0.2% Triton X-100 detergent for 5 min and then washed three
times with PBS. Staining was carried out according to the protocol
provided by the supplier (Upstate Technology). The TUNEL method
identifies apoptotic cells in situ by using terminal
deoxynucleotidyl transferase to transfer biotin-dUTP to the free 3
-OH
of cleaved DNA. The biotin-labeled cleavage sites then are visualized
reaction with fluorescein conjugated avidin (avidin-fluorescein
isothiocyanate). Photomicrographs were obtained with a fluorescence
microscope (Nikon).
Statistical analysis. Data are presented as the mean ± standard error for the indicated number of separate experiments. Statistical significance between drug-treated and untreated groups was evaluated by unpaired two-tailed Student's t test, and values of p < 0.05 were considered significant.
| |
Results |
|---|
|
|
|---|
Identification of cultured prostatic cells.
It has been well
reported that the human prostatic epithelial cells can successfully
proliferate in WAJC 404 medium rather than in RPMI-1640 medium
(Chaproniere and McKeehan, 1986
; Fong et al., 1991
). By
taking advantage of the different nutritional requirements for stromal
cells compared with that of epithelial cells, stromal cells were
successfully separated and cultured in RPMI-1640 medium containing 10%
FCS in this study. The purity of cultured prostatic stromal cells was
assessed by light microscopy and immunofluorescence staining of
vimentin, cytokeratin, smooth muscle
-actin, and desmin. Cultured
prostatic stromal cells exhibited a spindle-shaped morphology (Fig.
1A, C, E, and G) and demonstrated positive staining for vimentin (Fig. 1B), an intermediate
filament polypeptide that is specific for mesenchymal cells.
Prostatic epithelial cell contamination was ruled out by negative
immunostaining with epithelial cytokeratins (Fig. 1D). Furthermore, the
stromal cells exhibited immunoreactivity with smooth muscle
-actin
(Fig. 1F) and desmin (Fig. 1H); this staining pattern is consistent with smooth muscle differentiation. The cells did not exhibit contact
inhibition of growth because they proliferated at a steady rate. In
addition, culture morphology was characterized by the formation of
nodules of cells, that is, "hills and valleys" (data not shown),
similar to the configuration demonstrated by vascular SMCs in
vitro (Ross and Kariya, 1980
). It reveals that these cells are the
population of prostatic SMCs.
|
Correlation between cell number and absorbance value for MTT assay. We measured the correlation between cell number and absorbance value for MTT assay of prostatic SMCs. As shown in Fig. 2, there was a proportional increase in the absorbance values parallel to the increase in cell numbers with an r value of 0.997. These results indicate a very good correlation between the absorbance value and cell number and demonstrate that this MTT assay is suitable for the measurement of cell population.
|
Inhibition of cell proliferation by SNP and 8-bromo-cGMP. We examined the effect of SNP on the modulation of cell proliferation. Prostatic SMCs were made quiescent in serum-free RPMI-1640 medium for 48 hr before restimulation by the addition of serum. As shown in Fig. 3, FCS [10% (v/v)] significantly induced cell proliferation by 92.4%, 103.4%, 131.3%, and 112.5% above the pretreatment cell density for patient A, B, C, and D, respectively. SNP exhibited a concentration-dependent (0.1-10 µM) inhibitory action on FCS-induced cell proliferation. However, SNP had various degrees of antiproliferative potency in cultured cells from different patients with BPH; the maximal reduction in proliferation induced by SNP was 66.2%, 39.3%, 21.3%, and 33.3% for patient A, B, C, and D, respectively (Fig. 3). The effect of ODQ, a selective guanylate cyclase inhibitor, on SNP action also was examined. ODQ (3 µM), which alone did not modify the cell growth, significantly shifted upward the SNP-induced inhibition of cell proliferation (Fig. 4).
|
|
|
Effect of SNP on cellular cGMP accumulation. We measured the cellular cGMP content in RPMI-1640 medium, which is essentially the same medium used for the experiments on cell growth inhibition. SNP induced a concentration-dependent (0.1-3 µM) increase in intracellular cGMP content (Table 1). It showed that the concentration ranges for the stimulation of cGMP accumulation roughly corresponded with those for the inhibitory effects on cell proliferation.
|
Effect of SNP on serum-stimulated cell cycle. To determine when in the cell cycle SNP exerted its inhibitory effect on proliferation, subcultured SMCs were made quiescent by serum deprivation for 48 hr before restimulation with serum. SNP (10 µM) was added at various times after the addition of FCS [10% (v/v)] to serum-deprived cells. The data showed that the maximal inhibitory effect of cell proliferation occurred only when SNP was present within the first 6 hr after the readdition of serum and there was no significant effect on cell proliferation when SNP was added 18 hr after the serum refeeding (Fig. 6).
|
Effect of SNP on membrane-associated PKC activity. To elucidate whether the antiproliferative action of SNP involved a PKC-dependent pathway, quiescent human prostatic SMCs were stimulated by FCS [10% (v/v)], and protein kinase activity associated with the particulate fraction was measured. As a result, serum significantly increased the membrane-associated PKC activity (6.35 ± 1.02 pmol/min/106 cells, four experiments, p < 0.01 compared with basal activity of 1.38 ± 0.27 pmol/min/106 cells) in human prostatic SMCs. SNP (10 µM), which alone did not affect basal PKC activity (1.34 ± 0.28 pmol/min/106 cells), completely abolished the serum-induced augmentation of membrane-associated PKC activity (1.36 ± 0.04 pmol/min/106 cells, four experiments) (Fig. 7) This reveals that the SNP action likely is due mainly to the inhibition of a PKC-dependent pathway to cause the cell growth inhibition.
|
Effect of SNP on cell viability and apoptosis. The MTT assay method, trypan blue exclusion test, and TUNEL technique were used to examine the effect of SNP on cell viability and apoptosis. The results showed that the addition of SNP (10 µM) to human prostatic SMCs for 48 hr neither influenced the cell viability (98.8 ± 2.1% and 97.5 ± 1.2% survival compared with respective control by MTT assay and trypan blue exclusion test) nor induced the apoptosis (data not shown). These data suggest that SNP does not mediate its antiproliferative action via the cytotoxic effect and the induction of apoptosis.
| |
Discussion |
|---|
|
|
|---|
Initially, in this study we describe the isolation and
characterization of human prostatic stromal cells. This subculture monolayers exhibited the convex and spindle-shaped morphology, no
contact inhibition of growth, and a hill-and-valley growth pattern,
which were distinctive from the culture morphology and growth
characteristics of fibroblasts. As determined by immunocytochemical analysis of vimentin and cytokeratin in subcultures, the prostatic stromal cell outgrows without contamination of epithelial cells throughout the subcultivation. In addition, the stromal cells were
stained positive for smooth muscle
-actin and desmin; these results
are indicative of the smooth muscle differentiation. However, the
prostatic stromal cells cultured by Roberson et al. (1995)
stained positive for vimentin and fibronectin, lightly positive for
smooth muscle
-actin, and negative for desmin. Roberson et al. concluded that their stromal cells were myofibroblasts.
Nevertheless, the prostatic stromal cells cultured in our laboratories
not only showed the staining pattern of smooth muscle cells (positive
staining with smooth muscle
-actin and desmin) but also exhibited
some characteristics different from fibroblasts (Guh J-H, Hwang T-L, Teng C-M, unpublished observations), such as (1) basic fibroblast growth factor was a potent stimulator of human prostatic fibroblasts (Sherwood et al., 1992
; Story et al., 1993
) but
exhibited a weak mitogenic effect on cultured prostatic stromal cells
in our laboratories, and (2) the addition of an
1-adrenoceptor agonist (phenylephrine) to our
cultured stromal cells induced a significant increase in intracellular
Ca2+ mobilization, a pharmacological second
messenger in human prostatic SMCs. These data combined with the results
obtained from light microscopy and immunostaining verification and
characteristics of culture morphology revealed that our cultured
stromal cells resembled the prostatic SMC population. The use of these
cultures allowed us to study the effect of NO, endogenously synthesized in the prostate, on growth regulation of this cell type.
The MTT assay method was developed by Mosmann (1983)
in the early
1980s. During the past 14 years, this method has been used for the
measurement of both cell proliferation and cytotoxic effect on several
types of cells and provides reproducible and accurate measurements of
cell killing and proliferation compared with the [3H]thymidine incorporation assay and trypan
blue exclusion test. The loading time of MTT and the time for color
development were examined to establish the optimal conditions. The
results showed that the optimal conditions for these variables were 4 hr and 20-30 min, respectively (data not shown). Further
investigations were performed to measure the correlation between cell
number and absorbance value to examine whether this MTT assay method provided an accurate determination of human prostatic SMC
proliferation. As shown in Fig. 2, a direct correlation was found
between these two variables with an r value of 0.997, indicating that the MTT assay could be used for the measurement of
prostatic SMC proliferation.
The effect of SNP on cell proliferation was examined. The current
results clearly indicate that SNP can effectively inhibit FCS-induced
cell proliferation in human prostatic SMCs. In addition, the
antiproliferative action of SNP was mimicked by 8-bromo-cGMP, a
membrane-permeable cGMP analogue. Furthermore, SNP
concentration-dependently induced the cGMP formation. The concentration
ranges for the stimulation of cGMP accumulation by SNP were similar to
those necessary for the antiproliferative action. These results,
combined with the evidence that the antiproliferative action of SNP was
completely abolished by ODQ (3 µM, a selective guanylate
cyclase inhibitor) (Garthwaite et al., 1995
), revealed that
the antiproliferative action of SNP was mediated by the formation of
cGMP. Although there are findings that the relaxation of vascular
muscle in response to NO is mediated by cGMP-dependent and -independent
pathways (Moncada et al., 1991
; Bolotina et al.,
1994
), the SNP-induced inhibition of prostatic SMC proliferation in
this study apparently occurs via a cGMP-dependent mechanism. However,
the antiproliferative potencies of SNP varied among individual
prostatic SMCs, which were cultured from different patients with BPH.
It was likely due to the varying susceptibility to SNP in the cultured
cells of different patients.
It has been suggested that prostaglandin E1,
heparin, interferon-
, and cyclic nucleotide generating agent exert
their antiproliferative action through inhibition of the progression
from the G1 into the S phase of the cell cycle in
vascular SMCs, because they still inhibit the mitogen-induced DNA
synthesis and cell proliferation when added 6-12 hr after the initial
exposure of the cells to mitogens (Hoover et al., 1980
;
Nilsson and Olsson, 1984
; Fukumoto et al., 1988
; Guh
et al., 1996
). To define the inhibition point of the cell
cycle by SNP, human prostatic SMCs were synchronized to quiescent state
by serum deprivation and then stimulated to enter the cell cycle by
serum refeeding. The time of SNP (10 µM) exposure to
cultured cells was varied relative to the time of serum stimulation.
The results indicated that the maximal antiproliferative action
occurred only when SNP was present within the first 6 hr after the
initial exposure of serum. These data imply that SNP inhibits early
events in the G1 phase of the cell cycle.
PKC has been shown to be a key regulatory enzyme in the signal
transduction pathway leading to cell proliferation. It was found that
PKC acts as a positive regulator in the transition from the quiescent
to a proliferative state of the aortic SMCs (Ohmi et al.,
1990
) and plays a pivotal role in the signal transduction of
platelet-derived growth factor (Berridge, 1987
), epidermal growth
factor (Hunter et al., 1984
), and fibroblast growth factor (Feige and Baird, 1989
). Inhibitors of PKC activity such as H7 and
staurosporine suppressed cell proliferation induced by
phorbol-12-myristate-13-acetate or serum in vascular SMCs (Takagi
et al., 1988
; Matsumoto and Sasaki, 1989
; Ohmi et
al., 1990
). We examined the effect of serum on the
membrane-associated PKC activity as well as the inhibitory action by
SNP in human prostatic SMCs. The data showed that FCS [10% (v/v)]
caused a remarkable increase in membrane-associated PKC activity;
however, this stimulatory action by FCS was completely abrogated in the
presence of SNP (10 µM). In parallel experiments, we
examined the effect of PKC down-regulation on serum-induced prostatic
SMC proliferation and its influence on antiproliferative effect of SNP.
As a result, PKC down-regulation by the treatment of synchronized cells
with phorbol-12,13-dibutyrate (1 µM) for 24 hr
significantly reduced FCS-induced cell proliferation (~30%). Moreover, SNP was tested and found to be ineffective on the remaining cell proliferation induced by FCS via the PKC-independent pathway (data
not shown); that is, the inhibition of FCS-induced cell proliferation
by SNP was completely abolished by the inhibition of PKC activity.
Therefore, SNP may inhibit cell proliferation through inhibition of
PKC-dependent pathway in human prostatic SMCs.
It has been reported that NO exerts cytotoxic activity and causes cell
death in several cell types (Nathan, 1992
). Recently, a link was
proposed between NO formation and apoptosis (Albina et al.,
1993
; Sarih et al., 1993
; Member et al., 1995
).
To clarify whether SNP induced cell cytotoxic effect and apoptosis in
human prostatic SMCs, three independent assay techniques were used. The
trypan blue exclusion test and MTT assay were used to measure the
effect of SNP on cell cytotoxicity. The results showed that SNP had no
cytotoxic effect on prostatic SMCs at a concentration of <10
µM. Furthermore, with the use of TUNEL techniques, SNP (10 µM) also was found to not induce apoptosis in these
cultured cells.
Overall, our results suggest that the inhibition of a PKC-dependent
reaction is the major mechanism by which SNP suppresses FCS-induced
prostatic SMC proliferation. Furthermore, the antiproliferative effect
of SNP occurs at the early G1 phase of the cell
cycle. Moreover, there is increasing evidence that the small reduction in prostate size (~30%) significantly improves symptoms in men with
BPH (Gormley et al., 1992
; Stoner, 1992
; Nacey, 1994
).
Although the average antiproliferative effect of SNP was only 41.4%,
this could be effective in the relief of obstructive and irritating symptoms in patients with BPH. To date, no differences have been found
between growth factor or growth factor receptor levels in human BPH and
normal prostatic tissue (Bonnet et al., 1983
; Glynne-Jones et al., 1994
). In addition, no endogenous inhibitory
modulator in prostatic SMC growth has been found. In the current study, NO is shown to exert an antiproliferative action on human prostatic SMC
growth. We suggest it is a endogenous modulator of prostate growth that
could play a beneficial role in the restriction of prostate size.
| |
Acknowledgments |
|---|
We appreciate the generous supply of human prostatic tissues from Drs. Ming-Kun Lai, Jun Chen, and Cheng-Hsing Hsieh (Department of Urology, National Taiwan University Hospital, Taipei, Taiwan).
| |
Footnotes |
|---|
Received September 3, 1997; Accepted December 2, 1997
This work was supported by research grant NSC86-2314-B-002-297 from the National Science Council in Taiwan.
Send reprint requests to: Dr. Che-Ming Teng, Pharmacological Institutes, College of Medicine, National Taiwan University, No. 1, Jen-Ai Road, Sect. 1, Taipei, Taiwan.
| |
Abbreviations |
|---|
BPH, benign prostatic hyperplasia;
SMC, smooth muscle cell;
NO, nitric oxide;
SNP, sodium nitroprusside;
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide;
ODQ, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one;
HBSS, Hanks' balanced salt solution;
PBS, phosphate-buffered saline;
FCS, fetal calf serum;
TUNEL, terminal deoxynucleotidyl transferase
biotin-dUTP nick end labeling;
PKC, protein kinase C;
EGTA, ethylene
glycol bis(
-aminoethyl
ether)-N,N,N
,N
-tetraacetic
acid;
HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid.
| |
References |
|---|
|
|
|---|
-reductase and steroid hormone receptor messenger ribonucleic acid (mRNA) levels, but not in insulin-like growth factor mRNA levels.
J Clin Endocrinol Metab
77:
1203-1208[Abstract].
/
in rabbit aortic smooth muscle cells.
Biochem Biophys Res Commun
157:
337-345[Medline].
1 expression in benign and malignant prostatic tumors.
Prostate
25:
210-218[Medline].
1-adrenoceptor subtypes in tension response of human prostate to electrical field stimulation.
Br J Pharmacol
115:
142-146[Medline] .
-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group.
J Urol
147:
1298-1302[Medline].
1 and other growth factors on basic fibroblast growth factor level and proliferation of cultured human prostate-derived fibroblasts.
Prostate
22:
183-197[Medline]. This article has been cited by other articles:
![]() |
M. Schleicher and W. C. Sessa Are the Mechanisms for NO-Dependent Vascular Remodeling Different From Vasorelaxation In Vivo? Arterioscler. Thromb. Vasc. Biol., July 1, 2008; 28(7): 1207 - 1208. [Full Text] [PDF] |
||||
![]() |
B. Zhu, S. Strada, and T. Stevens Cyclic GMP-specific phosphodiesterase 5 regulates growth and apoptosis in pulmonary endothelial cells Am J Physiol Lung Cell Mol Physiol, August 1, 2005; 289(2): L196 - L206. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. D'Andrea, Y. Qiu, D. Haynes-Johnson, S. Bhattacharjee, P. Kraft, and S. Lundeen Expression of PDE11A in Normal and Malignant Human Tissues J. Histochem. Cytochem., July 1, 2005; 53(7): 895 - 903. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-T. Huang, D.-M. Huang, J.-H. Guh, I-L. Chen, C.-C. Tzeng, and C.-M. Teng CIL-102 Interacts with Microtubule Polymerization and Causes Mitotic Arrest following Apoptosis in the Human Prostate Cancer PC-3 Cell Line J. Biol. Chem., January 28, 2005; 280(4): 2771 - 2779. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. HORTELANO, A. M. ALVAREZ, and L. BOSCÁ Nitric oxide induces tyrosine nitration and release of cytochrome c preceding an increase of mitochondrial transmembrane potential in macrophages FASEB J, December 1, 1999; 13(15): 2311 - 2317. [Abstract] [Full Text] |
||||
![]() |
K. Yuasa, J. Kotera, K. Fujishige, H. Michibata, T. Sasaki, and K. Omori Isolation and Characterization of Two Novel Phosphodiesterase PDE11A Variants Showing Unique Structure and Tissue-specific Expression J. Biol. Chem., September 29, 2000; 275(40): 31469 - 31479. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||